Stay updated on Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check11 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check18 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2; the study page continues to display a 403 error.SummaryDifference0.2%

- Check25 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check32 days agoChange DetectedAccess to the study page now shows a 403 Forbidden error page instead of the expected content, with a Home link available. This indicates the page is blocked or access is restricted.SummaryDifference0.5%

- Check39 days agoChange DetectedAn error page (403 Forbidden) replaces the study record content, leaving only a basic header and a Home link. This prevents access to essential study details, locations, and related information.SummaryDifference22%

Stay in the know with updates to Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page.